# Feedback: Developing the payment system for 2021/22

This survey accompanies the tariff engagement document, *Developing the payment system for 2021/22.*

The deadline for submitting the survey is the end of **10 December 2020**.

Final survey responses should be submitted here: <https://www.engage.england.nhs.uk/pricing-and-costing/2021-22-tariff-engagement/>

## About you

|  |  |
| --- | --- |
| **Name** |  |
| **Role** |  |
| **Organisation** |  |
| **Email** |  |

## 

## Potential 2021/22 financial framework

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Were a financial framework based on the broad principles set out to be proposed, to what extent would you support such a move?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| Please explain the reasons for your answer | | | | | |
|  | | | | | |

|  |
| --- |
| **How do you think financial governance in your system would need to develop in order to support such a financial framework, were it to be implemented?** |
|  |

|  |
| --- |
| **Are there any areas in addition to the key considerations that you think we should be focusing on in developing a future financial framework?** |
|  |

|  |
| --- |
| **Do you have any other comments on the potential 2021/22 financial framework?** |
|  |

## Blended payment for 2021/22

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent do you agree that the blended payment approach would support the objectives of the NHS Long Term Plan?** | | | | | |
| Strongly agree | Agree | Neither agree nor disagree | Disagree | Strongly disagree | Don’t know |
| Please explain the reasons for your answer | | | | | |
|  | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support setting the scope of blended payment for almost all services covered by the national tariff?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support a simplified blended payment model, involving a fixed payment based on the costs to deliver a level of activity which conforms to the ICS system plan?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |
| **What guidance would you find most useful for agreeing the fixed payment locally?** | | | | | |
|  | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support the fixed payment including items currently excluded from the tariff, such as high cost drugs and devices and genomic tests?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would do you support including a variable element for some elective activity in the blended payment approach?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **If there were a variable element, would you prefer it to be:** | | | | | |
| * Entirely locally agreed * Mandated for inclusion but up to local systems to agree highest priority specialties and rates * 100% paid for elective activity above and below the level agreed * 75% paid for activity above plan and 25% for activity below plan * Nationally determined specialties have a 100% mandated variable payment | | | | | |
| **Please explain the reasons for your answers** | | | | | |
|  | | | | | |

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **To what extent would you support having a threshold provider/commissioner contract value below which the blended payment arrangements would not apply?** | | | | | | | | |
| Strongly support | Support | | Neither support nor oppose | | Oppose | Strongly oppose | | Don’t know |
| **If there were to be a threshold, do you think £10 million would be…** | | | | | | | | |
| **…too high?** | | **…about right?** | | **…too low?** | | | **Not sure** | |
| **Please explain the reasons for your answer** | | | | | | | | |
|  | | | | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support host CCGs paying for activity below £0.2m, with allocations adjusted to compensate?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **What would be your preferred default approach for contracts valued between £0.2m and £10m?** | | | | |
| Block contract | Activity-based payment | Blended payment arrangements | No default | Don’t know |
| **Please explain the reasons for your answer** | | | | |
|  | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support retaining national prices for diagnostic imaging services?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support a Standard Contract requirement for a System Collaboration and Financial Management Agreement alongside a blended payment, to help share risk across a system?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |
| **Do you have any comments on the 2020/21 model SCFMA, suggestions for how it could be improved or views on whether its focus should be broadened beyond financial balance?** | | | | | |
|  | | | | | |

## Financial incentives and best practice tariffs

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support a review of the financial sanctions for failure to achieve national performance standards in the NHS Standard Contract?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support the retirement of the day case and outpatient procedure BPTs if their financial incentives are replicated in a blended payment design?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

|  |
| --- |
| **To what extent would you support BPTs becoming non-mandatory with guidance on how to capture them within any blended payment agreements?** |
|  |
| Please explain the reasons for your answer |
|  |
| If this approach were taken, what guidance would you find most helpful to support use of existing BPTs within a blended payment arrangement? |
|  |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support the further integration and streamlining of financial incentives in future years?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |
| **What would be the key considerations for doing so effectively?** | | | | | |
|  | | | | | |

## Other tariff policy areas

### Length of tariff

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support setting the 2021 tariff for one year?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

### Adjustments to prices for Covid-19

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **To what extent would you support a local guidance framework for adjusting prices to account for costs arising from Covid-19?** | | | | | | |
| Strongly support | Support | Neither support nor oppose | | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | | |
|  | | | | | | |
| **What types of guidance framework would you find most useful?** | | | | | | |
| **Robustly detailed with standardised national requirements** | | | **Looser framework that could be flexibly applied to local requirements** | | | |
| **Please explain the reasons for your answer** | | | | | | |
|  | | | | | | |

### Rolling over price relativities

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support setting prices for 2021/22 by rolling over the price relativities and currencies from 2020/21?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

### Centralised procurement

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support making no further adjustments to the tariff to reflect the arrangements for the central funding of overhead costs of Supply Chain Coordination Limited (SCCL)?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

### Specialist top-ups and complexity

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support continuing to pause the specialist top-ups transition path for 2021/22?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |
| **Do you have any comments on the potential approach to specialist services top-ups for 2021/22?** | | | | | |
|  | | | | | |

### High cost exclusions

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support making no substantial changes to the high cost drugs and devices lists for 2021/22?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reasons for your answer** | | | | | |
|  | | | | | |

### Market forces factor (MFF)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **To what extent would you support moving to the next (third) step in the MFF glidepath introduced following the 2019/20 data and method update?** | | | | | |
| Strongly support | Support | Neither support nor oppose | Oppose | Strongly oppose | Don’t know |
| **Please explain the reason for your answer** | | | | | |
|  | | | | | |

## Future payment system development

|  |
| --- |
| **What would be your highest priority for any future payment system?** |
| * Whole system approach to payments, contracting and incentives * Improving payment building blocks such as costing and currency data * Enhancing data infrastructure and making better use of existing data. * The role of clinicians in payment decisions. * Exploring other approaches to calculating a fixed payment. * Aligning incentives for primary care and social care with those of the wider system. * Aligning quality incentives with system working and Long Term Plan objectives. * Supporting innovative contractual models. * Other |
| If 'other', please specify: |
| Please explain the reasons for your answer |
|  |
| **What forward guidance and information on national payment policy would you find helpful to support local planning and to successfully implement any new payment approach?** |
|  |

## Impact on equality and health inequalities

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **If they were implemented, what impact do you feel the policies outlined are likely to have on equality and addressing health inequalities?** | | | | | |
| Strong positive impact | Positive impact | Neither positive or negative impact | Negative impact | Strong negative impact | Don’t know |
| **Do you have concerns that there are distinct groups with protected characteristics that our policies may impact negatively?** | | | | | |
|  | | | | | |
| Please explain the reasons for your answers | | | | | |
|  | | | | | |

## Mental health currency developments

|  |
| --- |
| **Having read the document on the Mental Health currency review that accompanied Developing the payment system for 2021/22, are you able to give us your views on the questions raised:** |
| Are the proposed groups clinically meaningful, structured by disorder group and severity level? |
|  |
| Are the proposed groups administratively meaningful to support counting activity and payment? |
|  |
| With consideration to use by local systems and any additional burden or workload, should MHRGs be determined locally and flowed to the MHSDS, or should the individual items needed to determine the MHRG be flowed to the MHSDS i.e. disorder group, severity and setting, and MHRGs determined at a national level? |
|  |
| Should there be one review group for the whole model, or a number of different review groups providing input on each of the A. to G. disorder groups specifically? |
|  |

## Any other comments

|  |
| --- |
| **Do you have any other comments about the tariff or any other aspect of the payment system and wider NHS financial architecture?** |
|  |

|  |
| --- |
| **Do you have any comments or suggestions on how we could improve how we engage with you on our proposals?** |
|  |